Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Shares in the maker of Ozempic crashed to three-year low after the pharma giant warned its injections were losing ground to ...

Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk stock took a big hit early Tuesday after the Danish weight-loss drugmaker unexpectedly cut its full-year guidance for the U.S.It also announced a new CEO, appointing an insider to lead ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

If you’ve spent any time in the real world lately, chances are you’ve heard of Ozempic, Wegovy, Mounjaro or semaglutide.

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

A growing number of people are turning to medications like Ozempic, Wegovy, and Mounjaro to aid in weight loss and manage ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...